Table 2. Changes in 6MWD, ATGL protein, NYHA class, and TGCV severity score.

Endpoint		Placebo	CNT-01
6MWD (m)†	FAS	34.3 (−6.0 to 74.7)	34.1 (−3.9 to 72.1)
	PPS	34.3 (−8.0 to 76.5)	35.9 (−6.3 to 78.2)
ATGL protein mass (ng/mg of cell protein)†	FAS	3.00 (−1.12 to 7.12)	3.55 (−0.32 to 7.4)
	PPS	2.88 (−1.30 to 7.06)	4.19 (0.01 to 8.37)
NYHA class reduction (N)‡	FAS	1	0
TGCV severity score, symptom (SUM)§	FAS	−0.75 (−3.38 to 1.88)	−2.78 (−4.61 to −0.94)
TGCV severity score, ADL (SUM)§	FAS	−0.88 (−3.30 to 1.55)	−2.67 (−6.47 to 1.14)

^†Adjusted mean change from baseline (95% confidence intervals)

^‡Number of patients with more than 1 class reduction

^§Mean change from baseline (95% confidence intervals)

6MWD: 6-min walk distance, ADL: activity of daily living, ATGL: adipose triglyceride lipase, FAS: full analysis set, NYHA: New York Heart Association, PPS: per protocol set, TGCV: triglyceride deposit cardiomyovasculopathy